ClearPoint Neuro Q2 FY26 net loss widens to $11.34 million; revenue rises 18% to $10.9 million

Reuters2026/08/03 20:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ClearPoint Neuro posted Q2 revenue of $10.9 million, up 18% year over year; gross margin rose 2 percentage points to 62%.
Net loss widened to $11.34 million, or $0.38 per share, from $5.84 million, or $0.21 per share, a year earlier.
Operating loss expanded to $10.24 million from $5.68 million; operating expenses climbed 51% to $17 million, driven by the IRRAS acquisition.
Biologics and drug delivery revenue fell 15% to $4 million on lower biopharma trial-initiation shipments; neurosurgery navigation and therapy revenue jumped 62% to $5.6 million.
ClearPoint cut 2026 revenue guidance to $48 million-$52 million, citing increased investment in clinical capacity, CAL expansion, focused ultrasound, robotics, and Harmony software.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608031605ACCESSWRNAPR_____1200753) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ClearPoint Neuro Q2 FY26 net loss widens to $11.34 million; revenue rises 18% to $10.9 million

You may also like

Crypto prices